Skip to Primary Navigation

Skip to main content

Patients Choice Laboratories pays over $9m to settle FCA allegations

A scientist handles specimens of Influenza A Virus.
Photo: Smith Collection/Gado/Getty Images

Kevin Kinsella

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The DOJ said the case demonstrates government emphasis on combating healthcare fraud, particularly through use of the FCA.

According to the US Department of Justice (DOJ), Patients Choice Laboratories (PCL), an Indianapolis-based diagnostic laboratory company, has agreed to pay $9.6m to resolve allegations that it violated the False Claims Act (FCA) and the Anti-Kickback Statute (AKS).

DOJ said PCL did so by knowingly filing claims to

, , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience